CClinicalTrials.gg
Status unknownNCT03147014Updated Dec 4, 2018

Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease

An interventional study of Maternal hyperoxygenation in Hypoplastic Left Heart Syndrome, Aortic Coarctation and Atrial Septal Aneurysm, sponsored by Beijing Anzhen Hospital. Status unknown at 1 site in China. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Sex
Female
01

Study summary

Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease

Read the detailed description

The purpose of this study is to investigate the phenomenon of cardiovascular system response to maternal hyperoxygenation in the fetus with congenital heart disease(CHD), which can provide further insight into fetal adaptations to CHD and improve our understanding of the pathophysiology of these conditions.Cases are gravidas with fetal congenital heart disease diagnosed by echocardiography various gestational weeks.The baseline fetal echocardiography parameters has obtained from these gravidas.Then the participants received 10-15 minutes hyperoxygenation, and the accordingly fetal echocardiography parameters were obtained.The objective of the study includes:(1)To investigate the response of the MCA PI to maternal hyperoxygenation in various forms of CHD. Middle cerebral artery(MCA) pulsatility index (PI) at MH will be compared to baseline at various gestational ages in a variety of types of CHD;(2)To investigate the response of the umbilical artery (UA) PI to maternal hyperoxygenation in various forms of CHD. UA PI at MH will be compared to baseline at various gestational ages in a variety of CHD; (3)To study the response of myocardial diastolic function to MH in various forms of CHD. Diastolic inflow patterns across the tricuspid and mitral valves will be measured and ductus venosus flow pattern will be evaluated at MH and compared to baseline at various gestational ages in a variety of CHD;(4)To investigate for any changes in cardiac output and the ratio of flow between the right and left ventricles in response to MH in various forms of CHD;(5)To investigate for changes in flow pattern at the aortic isthmus in those with suspicion or clear evidence of coarctation of the aorta.

02

Conditions studied

  • Hypoplastic Left Heart Syndrome
  • Aortic Coarctation
  • Atrial Septal Aneurysm

Keywords

  • Echocardiography
  • Congenital Heart Disease
  • Maternal hyperoxygenation
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • All singleton fetuses with CHD at all gestational ages are eligible for enrollment in the study. Patients will be recruited to enroll in the study as they present for clinical care at Fetal Echocardiography clinic. MH assessments will all be performed only at the Beijing Anzhen Hospital. Baseline room air data for CHD may be collected from other referring centers within the Anzhen network.

Exclusion criteria

Exclusion Criteria:

  • Non-sinus rhythm, presence of arrhythmia; Fetal hydrops; Severe brain anomaly (which may influence MCA flow); Evidence for significant ventricular dysfunction; Evidence for constriction of the ductus arteriosus
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Other
    Maternal Hyperoxygenation

    Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.

    Biological: Maternal hyperoxygenation

Interventions

  • BiologicalMaternal hyperoxygenation

    approximately 10-15 minutes of maternal hyperoxygenation

05

What researchers measure

Primary outcomes

  1. MCA PI change before and after maternal hyperoxygenation

    The response of the MCA PI to maternal hyperoxygenation in various forms of CHD. MCA PI at MH will be compared to baseline at various gestational ages in a variety of types of CHD.

    Time frame: 10-15 minutes

Secondary outcomes

  1. UA PI change before and after maternal hyperoxygenation

    Response of the umbilical artery (UA) PI to maternal hyperoxygenation in various forms of CHD. UA PI at MH will be compared to baseline at various gestational ages in a variety of CHD.

    Time frame: 10-15 minutes

Other outcomes

  1. Response of myocardial diastolic function to MH in various forms of CHD

    Diastolic inflow patterns across the tricuspid and mitral valves will be measured and ductus venosus flow pattern will be evaluated at MH and compared to baseline at various gestational ages in a variety of CHD.

    Time frame: 10-15 minutes

  2. Systolic function change before and after MH

    any changes in cardiac output and the ratio of flow between the right and left ventricles in response to MH in various forms of CHD.

    Time frame: 10-15 minutes

  3. Changes in flow pattern at the aortic isthmus

    Changes in flow pattern at the aortic isthmus in those with suspicion or clear evidence of coarctation of the aorta

    Time frame: 10-15 minutes

06

Study locations

1 of 1 sites recruiting
  • Beijng Anzhen Hospital
    Beijing, Beijing 100029, China
    Recruiting
07

Registry details

Key details

Study ID
NCT03147014
Lead sponsor
Beijing Anzhen Hospital
Responsible party
He Yihua,MD (Director of Department of Ultrosound, Beijing Anzhen Hospital) — Principal investigator
First posted
May 10, 2017
Start date
Jan 1, 2016
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Dec 4, 2018

Study contacts

Yanping Ruan, MD
Contact
yanping.ruan@163.com
+86 15311258732
Yihua He, MD
Contact
heyihuaecho@hotmail.com
+86 18910778673 ext. +8618910778673
Yihua He, MD
study director · Beijing Anzhen Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion